THE IBN SINA PHARMACEUTICAL INDUSTRY PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 251.8 BDT | +0.48% |
|
-0.87% | -12.14% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 65% by 2026.
- With a P/E ratio at 11.04 for the current year and 9.68 for next year, earnings multiples are highly attractive compared with competitors.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.14% | 67.03M | - | ||
| +21.09% | 43.27B | B- | ||
| +25.39% | 22.92B | B+ | ||
| +19.22% | 15.43B | - | ||
| +13.51% | 12.95B | B+ | ||
| +44.01% | 11.83B | B | ||
| -6.70% | 6.91B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +13.26% | 5.55B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
- Stock Market
- Equities
- IBNSINA Stock
- Ratings The IBN SINA Pharmaceutical Industry PLC